Treatment Resistant Depression Epidemiology Forecast 2025-2034

According to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), treatment-resistant depression is defined as an inadequate response to at least two antidepressants despite adherence to the treatment and adequacy of the treatment trial. Current estimates suggest that about 30% of individuals with depression experience treatment-resistant depression.

Treatment Resistant Depression Epidemiology Forecast Report Coverage

The “Treatment Resistant Depression Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of treatment resistant depression. It projects the future incidence and prevalence rates of treatment resistant depression across various populations. The study covers age and type as major determinants of the treatment resistant depression-affected population. The report highlights patterns in the prevalence of treatment resistant depression over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of treatment resistant depression in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Treatment Resistant Depression: Disease Overview

Treatment resistance depression (TRD) is a challenging and complex type of depression, where people with major depressive disorder fail to respond adequately to at least two different antidepressant treatments of appropriate dosage and duration. The exact cause of treatment resistance depression is not known but may involve a combination of genetic, environmental, and biological factors. This condition is linked with functional impairment and a higher likelihood of suicidal ideation. Treatment resistance depression is more prevalent in females and older adults and imposes a substantial healthcare burden.

Treatment Resistant Depression: Treatment Overview

Management of treatment-resistant depression typically includes trying different approaches when standard treatments don’t work, with the focus on finding the right combination of therapies. The affected patients are often switched to a different type of antidepressant, like tricyclic antidepressants (TCAs) or monoamine oxidase inhibitors (MAOIs), or prescribed additional medications, such as antipsychotics, lithium, or thyroid hormones, to boost the effects of antidepressants. Some healthcare providers also recommend a combination of antidepressants for better results.

Epidemiology

The treatment resistant depression epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for treatment resistant depression by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for treatment resistant depression and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• It is estimated that 30% of individuals who have been diagnosed with major depressive disorder and who have taken medications for the condition have experienced treatment-resistant depression.
• Treatment resistant depression is a type of major depressive disorder (MDD), with the patients more likely to have more severe symptoms and depressive episodes that last longer. Major depressive disorder affects around 5% to 17% of the population at some point in their lives.
• Women are 2.6 times more likely than men to have issues with both major depressive disorder and treatment-resistant depression, suggesting that factors in their lives and biology contribute to a higher risk of depression.
• Individuals with treatment resistant depression are twice as likely to experience chronic pain, anxiety disorders, and fibromyalgia. The average medical service cost of treatment resistant depression episodes ranges from USD 5,000 to USD 10,000 per visit.

Country-wise Treatment Resistant Depression Epidemiology

The treatment resistant depression epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of treatment resistant depression varies significantly between countries due to differences in the treatment availability and accessibility, cultural attitudes toward mental health, diagnostic criteria, and socioeconomic factors. Genetic predispositions and lifestyle factors, such as diet, physical activity, and substance use, also influence the prevalence across populations. In India, the prevalence of depressive disorders is reported to be 2.7% by the National Mental Health Survey.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of treatment resistant depression based on several factors.
• Treatment Resistant Depression Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of treatment resistant depression are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of treatment resistant depression epidemiology in the 8 major markets?
• What will be the total number of patients with treatment resistant depression across the 8 major markets during the forecast period?
• What was the country-wise prevalence of treatment resistant depression in the 8 major markets in the historical period?
• Which country will have the highest number of treatment resistant depression patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of treatment resistant depression during the forecast period of 2025-2034?
• What are the currently available treatments for treatment resistant depression?
• What are the disease risks, signs, symptoms, and unmet needs of treatment resistant depression?

This product will be delivered within 3-5 business days.